Liposomal-Glutathione Provides Maintenance of Intracellular Glutathione and Neuroprotection in Mesencephalic Neuronal Cells
- 415 Downloads
A liposomal preparation of glutathione (GSH) was investigated for its ability to replenish intracellular GSH and provide neuroprotection in an in vitro model of Parkinson’s disease using paraquat plus maneb (PQMB) in rat mesencephalic cultures. In mixed neuronal/glial cultures depleted of intracellular GSH, repletion to control levels occurred over 4 h with liposomal-GSH or non-liposomal-GSH however, liposomal-GSH was 100-fold more potent; EC50s 4.75 μM and 533 μM for liposomal and non-liposomal-GSH, respectively. Liposomal-GSH utilization was also observed in neuronal cultures, but with a higher EC50 (76.5 μM), suggesting that glia facilitate utilization. Blocking γ-glutamylcysteine synthetase with buthionine sulfoxamine prevented replenishment with liposomal-GSH demonstrating the requirement for catabolism and resynthesis. Repletion was significantly attenuated with endosomal inhibition implicating the endosomal system in utilization. Liposomal-GSH provided dose-dependent protection against PQMB with an EC50 similar to that found for repletion. PQMB depleted intracellular GSH by 50%. Liposomal-GSH spared endogenous GSH during PQMB exposure, but did not require GSH biosynthesis for protection. No toxicity was observed with the liposomal preparation at 200-fold the EC50 for repletion. These findings indicate that glutathione supplied in a liposomal formulation holds promise as a potential therapeutic for neuronal maintenance.
KeywordsGlutathione Neurodegeneration Autism Schizophrenia Parkinson’s disease
This work was supported by a grant from Your Energy Systems, LLC and from The National Institutes of Health (NS36157). As a study sponsor, Your Energy Systems, LLC played no role in the study design, data acquisition, analysis or writing of the report for publication.
- 10.James SJ, Cutler P, Melnyk S, Jernigan S, Janak L, Gaylor DW, Neubrander JA (2004) Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutri 80:1611–1617Google Scholar
- 20.Sekhon B, Sekhon C, Khan M, Patel SJ, Singh I, Singh AK (2003) N-Acetyl cysteine protects against injury in a rat model of focal cerebral ischemia. Brain Res 971:1–8Google Scholar
- 22.Janaky R, Ogita K, Pasqualotto BA, Bains JS, Oja SS, Yondea Y, Shaw CA, (1999) Glutathione and signal transduction in the mammalian CNS. J Neurochem 73:889–902Google Scholar
- 35.Gibson AE, Noel RJ, Herlihy JT, Ward WF (1989) Phenylarsine oxide inhibition of endocytosis: effects on asiolofetuin internalization, Am. J Physiol Cell Physiol 257:C182–C184Google Scholar
- 39.Meco G, Bonifati V, Vanacore N, Fabrizio E (1994) Parkinsonism after chronic exposure to the fungicide maneb (manganese ethylene-bis-dithiocarbamate. Scan J Work Environ Health 20:301–305Google Scholar
- 57.Kannan R, Kuhlenkamp JF, Jeandidler E, Trinh H, Ookhetens M, Kkaplowitz N (1990) Evidence for carrier-mediated transport of glutathione across the blood brain barrier in the rat. J Clin Invest 85:2009–2013Google Scholar
- 62.Cheng FC, Kuo JS, Chia LG, Dryhurst G (1996) Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson’s disease. J Neural Transmission 103:433–446CrossRefGoogle Scholar